紫杉醇腹腔灌注联合替吉奥治疗晚期胃癌腹膜转移的研究进展  

The progress of the research on paclitaxel intraperitoneal perfusion combined with S-1,gimeracil and oteracil potassium capsules against peritoneal metastasis of advanced gastric cancer

作　　者：郭健[1] 郑龙志[1] 林伟[1] GUO Jian;ZHENG Longzhi;LIN Wei(Department of Gastroenterology,the Affiliated Hospital of Putian University,Fujian,Putian 351100,China)

机构地区：[1]莆田学院附属医院胃肠外一科,福建莆田351100

出　　处：《中国医药科学》2020年第16期40-44,共5页China Medicine And Pharmacy

基　　金：福建省莆田学院校内附属医院科研项目(2017046)。

摘　　要：胃癌是我国最常见的消化道肿瘤,但大多数胃癌患者发现时已是中晚期,其中包括了部分晚期胃癌合并腹膜转移的患者。化疗是目前治疗晚期胃癌腹膜转移的主要手段,腹腔灌注紫杉醇和单药替吉奥(S-1)都被分别证实对胃癌腹膜转移有一定的疗效。目前国内外尤其是日本开展了大量腹腔灌注紫杉醇联合口服替吉奥治疗晚期胃癌腹膜转移的临床研究,结果表明该联合化疗方案安全、有效,可以显著改善患者的总生存率及中位生存时间,值得进一步研究及推广。Gastric cancer(GC)is the commonest digestive tract tumor in China,but most cases of GC were found to be in an advanced stage for the patients,including some patients with advanced GC complicated with peritoneal metastasis.Chemotherapy is currently the main method for the treatment of peritoneal metastasis of advanced GC.Intraperitoneal perfusion of paclitaxel and the single drug of S-1,gimeracil and oteracil potassium capsules(S-1)have been proved to have certain therapeutic effects on peritoneal metastasis of GC respectively.At present,a large number of clinical studies on intraperitoneal perfusion of paclitaxel combined with oral S-1 for the treatment of peritoneal metastasis of advanced GC have been carried out at home and abroad,especially in Japan.The results showed that the combined chemotherapy scheme is safe and effective.It can significantly improve the overall survival rate and prolong the median survival time of the patients.It is worthy of further research and promotion.

关 键 词：晚期胃癌 腹膜转移 紫杉醇 腹腔灌注 替吉奥 

分 类 号：R735.2[医药卫生—肿瘤]